tiprankstipranks
Trending News
More News >
Xintela AB (SE:XINT)
:XINT

Xintela AB (XINT) AI Stock Analysis

Compare
0 Followers

Top Page

SE

Xintela AB

(Frankfurt:XINT)

Rating:43Neutral
Price Target:
Xintela AB's stock is facing significant financial challenges, with persistent losses and negative equity being major concerns. The recent revenue growth is a positive sign but is overshadowed by the company's dependence on external financing and unprofitability. Technical indicators show a mixed outlook, while valuation metrics reflect the company's financial instability. Overall, Xintela AB requires substantial improvement to become a more attractive investment.

Xintela AB (XINT) vs. iShares MSCI Sweden ETF (EWD)

Xintela AB Business Overview & Revenue Model

Company DescriptionXintela AB (XINT) is a biotechnology company based in Sweden that focuses on the development and commercialization of cell therapy products and targeted cancer treatments. The company leverages its proprietary marker technology, XINMARK, to identify and select specific cell types for therapeutic use, primarily in the fields of regenerative medicine and oncology. Xintela's core products and services revolve around stem cell-based therapies for osteoarthritis and other musculoskeletal disorders, as well as targeted antibodies for the treatment of aggressive cancers.
How the Company Makes MoneyXintela AB primarily generates revenue through the development and commercialization of its proprietary cell therapy products and targeted cancer treatments. The company earns money by partnering with pharmaceutical companies and research institutions to co-develop therapies, licensing its technology, and potentially through future product sales once regulatory approvals are secured. Significant factors contributing to its earnings include collaborative agreements, research grants, and strategic partnerships that support the advancement of its clinical programs. Additionally, Xintela may benefit from milestone payments and royalties from commercialized products developed using its technology.

Xintela AB Financial Statement Overview

Summary
Income Statement
Balance Sheet
Cash Flow
Breakdown
TTMDec 2023Dec 2022Dec 2021Dec 2020Dec 2019
Income StatementTotal Revenue
3.20M78.00K0.000.000.0038.00K
Gross Profit
2.26M78.00K-3.79M-3.50M-3.57M5.68M
EBIT
-41.46M-57.24M-69.06M-43.56M-33.90M-38.05M
EBITDA
-39.14M-53.47M-64.83M-57.11M-30.33M-33.92M
Net Income Common Stockholders
-40.48M-54.08M-66.22M-58.93M-52.92M-43.55M
Balance SheetCash, Cash Equivalents and Short-Term Investments
20.99M7.81M8.34M9.94M33.60M412.00K
Total Assets
39.40M18.39M24.52M24.74M48.51M17.09M
Total Debt
0.000.000.000.0010.90M0.00
Net Debt
-20.99M-7.81M-8.34M-9.94M-22.70M-412.00K
Total Liabilities
3.91M14.02M18.74M20.80M20.91M7.77M
Stockholders Equity
35.48M4.38M5.78M3.95M27.61M9.32M
Cash FlowFree Cash Flow
-17.80M-53.22M-39.60M-44.15M-21.71M-32.51M
Operating Cash Flow
-17.80M-53.12M-39.49M-42.89M-21.33M-30.89M
Investing Cash Flow
0.00-104.00K-27.52M-1.20M-329.00K-2.53M
Financing Cash Flow
7.08M51.79M64.56M20.43M54.85M2.44M

Xintela AB Technical Analysis

Technical Analysis Sentiment
Positive
Last Price0.46
Price Trends
50DMA
0.41
Positive
100DMA
0.41
Positive
200DMA
0.41
Positive
Market Momentum
MACD
<0.01
Positive
RSI
57.25
Neutral
STOCH
50.48
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:XINT, the sentiment is Positive. The current price of 0.46 is above the 20-day moving average (MA) of 0.43, above the 50-day MA of 0.41, and above the 200-day MA of 0.41, indicating a bullish trend. The MACD of <0.01 indicates Positive momentum. The RSI at 57.25 is Neutral, neither overbought nor oversold. The STOCH value of 50.48 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SE:XINT.

Xintela AB Peers Comparison

Overall Rating
UnderperformOutperform
Sector (62)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
62
Neutral
$11.80B10.31-7.45%2.91%7.43%-7.78%
48
Neutral
kr379.37M-47.73%45.52%93.35%
47
Neutral
€78.79M-69.81%-17.91%22.80%
44
Neutral
kr267.41M-18.79%21.85%
SEACE
43
Neutral
€563.30M-138.29%39.92%
43
Neutral
kr305.60M
5303.85%55.59%
36
Underperform
€185.74M-54.29%-100.00%-17.35%
* Technology Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
SE:XINT
Xintela AB
0.46
0.20
79.30%
SE:ACE
Ascelia Pharma AB
4.84
-1.68
-25.80%
SE:IMMU
Immunicum AB
5.18
-4.40
-45.93%
SE:ISOFOL
Isofol Medical AB
1.14
0.43
59.55%
SE:NXTCL
NextCell Pharma AB
1.06
-0.45
-29.93%
SE:XBRANE
Xbrane Biopharma AB
0.23
-0.07
-24.18%
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.